Koselugo

Active Ingredient(s): Selumetinib Sulfate
FDA Approved: * April 10, 2020
Pharm Company: * ASTRAZENECA PHARMS
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Koselugo Overview

Selumetinib (INN),[3] sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves.[4] It is taken by mouth twice per day on an empty stomach.[5] Common side effects include headache, abdominal pain and other problems of the gastrointestinal tract, fatigue, muscle pain, as well as dry s...

Read more Koselugo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Selumetinib

Recent Koselugo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Selumetinib Sulfate
  • Capsule: 10mg, 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Koselugo: (2 results)

Sorted by National Drug Code
  • 0310-0610 Koselugo 10 mg Oral Capsule by Astrazeneca Pharmaceuticals Lp
  • 0310-0625 Koselugo 25 mg Oral Capsule by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Selumetinib Sulfate or a similar ingredient: (1 result)